Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback 3Q 2025 private placement, together with October financings, generated approximately $25.7M in cash and cash commitments to support accelerated development of... Read More

ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price of $1.62 per share and a concurrent private placement of... Read More

ALAMEDA, Calif., Oct. 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 6,000,000 shares of its common stock at an offering price of $1.62 per share and concurrent private placement of 3,703,703 shares of its... Read More

ALAMEDA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that Chief Executive Officer Adam Mendelsohn, Ph.D., will provide a Company Presentation at the ThinkEquity Conference on October 30, 2025 in New York. Event details are as follows: Presentation... Read More

The Company expects to reestablish and announce a new record date as soon as possible ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that the Company will temporarily withdraw the previously announced record date for the planned spin-off of... Read More

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s new Orion ® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new... Read More

NPM-139 has potential to provide Wegovy ® -level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM-139 to occur in parallel with Phase 1 study ALAMEDA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a... Read More

ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10,... Read More

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $ 10 M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that... Read More

LIBERATE-1, the first-in-human application of Vivani’s NanoPortal TM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met the study’s primary objectives New NPM-139 (semaglutide implant) preclinical feasibility data showed approximately 20% weight loss maintained longer than 6 months with a single implant, continuing to support the potential for... Read More

ALAMEDA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of Anthony Baldor as Chief Financial Officer. Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus on her board appointments and personal projects after a... Read More

ALAMEDA, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the 2025 BIO International Convention , taking place from June 16-19, 2025 in Boston,... Read More

Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion ® Visual Cortical Prosthesis System to provide meaningful visual perception to people who are blind Cortigent is developing the Stroke Recovery System to improve the recovery of arm and hand movement in people who have suffered... Read More

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1™ study in obese or overweight individuals; top-line results are anticipated in mid-2025 Announced new $3M equity financing together with the previously reported $8.25M equity financing secures financial position into mid-2026 Promising pre-clinical data released for NPM-139... Read More

ALAMEDA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the American Association of Pharmaceutical Scientists’ (AAPS) “Beyond GLP1s: Where the Science will Take... Read More

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company’s LIBERATE-1 clinical trial from which topline data is anticipated in mid-year 2025 ALAMEDA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage... Read More

ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. ("Okava"), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the... Read More

Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic®/Wegovy®, with potential for once-yearly dosing Additional $8.25M equity financing which... Read More

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature,... Read More

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature,... Read More

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80 th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register... Read More

ALAMEDA, Calif. / Mar 24, 2025 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on March 27, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive... Read More

Miniature, twice-yearly GLP-1 (exenatide) implant under development for chronic weight management NPM-115 has demonstrated comparable preclinical weight loss to injections of semaglutide, the active ingredient in Ozempic®/Wegovy® Rapid full study enrollment with all 24 subjects initiating the 8-week run-in period within four weeks; top-line study results expected in mid-2025 ALAMEDA, Calif. / Mar 13, 2025 / Business Wire /... Read More

Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent shareholders Cortigent’s Orion ® artificial vision system, which is in development to treat blindness, completed an initial 6-year clinical study in 2024, with encouraging safety and efficacy results Formerly Second Sight Medical Products, Cortigent achieved the first and only FDA authorization (under a Humanitarian Device Exemption) for an... Read More

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration Study represents the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Dec 19, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative... Read More

ALAMEDA, Calif. / Dec 04, 2024 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present and participate in a panel discussion at the Innovation in Obesity Therapeutics Summit West Coast, taking place in San Diego, California, from December... Read More

Regulatory approval to initiate first-in-human study with a miniature, ultra long-acting GLP-1 (exenatide) implant in obese or overweight individuals in Australia Miniature, ultra long-acting GLP-1 implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Announces $5M equity financing which secures solid financial position into... Read More

ALAMEDA, Calif. / Oct 22, 2024 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at two upcoming events in October: (1) Partnership Opportunities in Drug Delivery (PODD), taking place in Boston on October 28 and 29, 2024 and (2) the ThinkEquity Conference,... Read More

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, the active ingredient in Ozempic®/Wegovy®, with twice-yearly administration Study will represent the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Sep 26, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani”... Read More

ALAMEDA, Calif. / Sep 23, 2024 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024. Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive... Read More

Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously announced sham-implant adjusted preclinical weight loss of 20%, which is comparable to the weight loss produced from the... Read More

ALAMEDA, Calif. / Aug 28, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company developing miniature, ultra long-acting, subdermal drug implants, today announced its plans to participate in the H.C. Wainwright 26 th Annual Global Investment Conference taking place September 9-11, 2024 in New York, New York. Vivani’s Chief Executive Officer, Adam... Read More

Initiation of the NPM-115 clinical program expected in the fourth quarter of 2024 with a first-in-human study evaluating a miniature, subdermal GLP-1 (exenatide) implant in obese or overweight patients FDA provided clearance of the Investigational New Drug Application for NPM-119, providing further confidence to advance the Company’s emerging portfolio of GLP-1 implants into clinical phase development Solid financial... Read More

Vivani expects to initiate the first clinical study supporting the NPM-115 program in the fourth quarter of 2024 The NPM-115 clinical program will consist of a series of studies designed to support the development of Vivani’s miniature, 6-month GLP-1 (exenatide) NanoPortal™ implant for chronic weight management in obese or overweight patients ALAMEDA, Calif. / Jul 11, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq:... Read More

NPM-119 is being studied to address medication non-adherence and potentially improve tolerability issues associated with oral and injectable type 2 diabetes medications, by providing long-term therapeutic delivery of exenatide for six months Study will represent first clinical application of NanoPortal™, the company’s proprietary, implant platform technology ALAMEDA, Calif. / Jun 13, 2024 / Business Wire / Vivani Medical,... Read More

Data Published in BMC Veterinary Research shows that OKV-119 exenatide implant reduced feline weight Felines share many pathophysiologic obesity phenotypes with humans, further supporting clinical evaluations of miniature, subdermal GLP-1 implants for obesity reduction Development partner, Okava Pharmaceuticals, is studying OKV-119 for the treatment of pre-diabetes, diabetes, and obesity in companion felines ALAMEDA, Calif.... Read More

Company continues advancing the development of miniature, long-term GLP-1 implants for the treatment of chronic weight management in obese or overweight patients, type 2 diabetes, and other chronic diseases Stable financial position supports operations into the second half of 2025 and potential delivery of key portfolio milestones ALAMEDA, Calif. / May 13, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani”... Read More

ALAMEDA, Calif. / May 09, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset NPM-115 for chronic weight management in obese or overweight patients with one or more risk factors, today announced that it will present at the TIDES Conference 2024 at 4:30 p.m. ET at the Hynes Convention... Read More

Strategic shift prioritizes the development of GLP-1 implants for the treatment of obesity and chronic weight management Positive NPM-115 (exenatide implant) preclinical weight loss data comparable to semaglutide, active ingredient in Ozempic ® /Wegovy ® $15 million financing round enables acceleration of priority development programs and secures operations into the second half of 2025 ALAMEDA, Calif. / Mar 26, 2024 /... Read More

Appointment comes as Vivani prioritizes the development of its GLP-1 implants for the treatment of obesity and chronic weight management Under Bradbury’s leadership as CEO, Amylin Pharmaceuticals, with partner Alkermes, secured in 2012 approval of Bydureon® (exenatide injection), the world’s first once-weekly GLP-1 receptor agonist, a class of drugs that now includes blockbusters Ozempic®, Trulicity®, and Wegovy® ALAMEDA,... Read More

ALAMEDA, Calif. / Mar 01, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today announced that it has entered into a securities purchase agreement with an institutional investor to purchase 3,947,368 shares of common stock and warrants to purchase up to an aggregate of 3,947,368 shares... Read More

NPM-115 (exenatide implant) generated significant weight loss comparable to injectable semaglutide (Ozempic®/Wegovy®) from a single administration with expected twice-yearly dosing Vivani discloses semaglutide as the active pharmaceutical ingredient in NPM-139, with the added potential benefit of once-yearly dosing NPM-115 and... Read More

Company announces addition of NPM-115 (high-dose exenatide implant) to its emerging pipeline, a potential alternative to life-long injections or pills for long-term GLP-1 therapy for the treatment of chronic weight management in obese or overweight patients Vivani is actively engaged in discussions with the US FDA to enable the expeditious initiation of LIBERATE-1, proposed FIH study of NPM-119 in patients with type 2... Read More

ALAMEDA, Calif. / Oct 16, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the BIO Investor Forum at 2:00 p.m. PDT at the Hilton San Francisco Union Square on October 18, 2023. Vivani President and Chief Executive Officer Adam Mendelsohn,... Read More

ALAMEDA, Calif. / Sep 07, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced today that it will present at the upcoming Annual Boulder Peptide Symposium at 11:20 am PST at the Napa Valley Marriott Hotel and Spa in Napa, California on September 19, 2023. Dr. Adam Mendelsohn,... Read More

EMERYVILLE, Calif. / Sep 05, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, announced today that its wholly-owned subsidiary Cortigent, Inc., a company pioneering targeted neurostimulation technology to recover critical body functions, will present the Early Feasibility Study (EFS) results for the Orion ® Visual... Read More

EMERYVILLE, Calif. / Aug 14, 2023 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, preclinical-stage biopharmaceutical company developing novel, long-term drug implants, today reported financial results for the second quarter of 2023 and provided a business update. Vivani™ continues to advance its emerging portfolio of innovative, highly differentiated drug implants leveraging... Read More

EMERYVILLE, Calif. / Jul 11, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI), an innovative, near-clinical stage biopharmaceutical company that is developing novel, miniature, long-term therapeutic implants, announced today that its wholly-owned subsidiary Cortigent, Inc., a company pioneering neurostimulation to recover critical body function, has completed the fifth year of its Early Feasibility Study (EFS) of... Read More

EMERYVILLE, Calif. / Jun 14, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, near clinical-stage biopharmaceutical company that develops novel, miniature, long-term therapeutic implants, announced today that Company CEO Adam Mendelsohn, Ph.D. has been invited to participate at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.... Read More

EMERYVILLE, Calif. / May 15, 2023 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product NPM-119 for the treatment of patients with type 2 diabetes and/or obesity, today reported financial results for the first quarter and provided a business update. NPM-119 is a preclinical stage, 6-month, GLP-1... Read More

EMERYVILLE, Calif. / Apr 04, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an emerging biopharmaceutical company which develops miniaturized, subdermal implants today announced that the Company received notice from the National Institutes of Health (“NIH”) of approval of the year 5 funding for the Early Feasibility Clinical Study of the Orion Visual Cortical Prosthesis being... Read More

EMERYVILLE, Calif. / Mar 31, 2023 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants, including lead product candidate NPM-119 for the treatment of patients with type 2 diabetes, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. According to... Read More

EMERYVILLE, Calif. / Mar 21, 2023 / Business Wire / Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, today announced the filing of a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) for the proposed initial public offering of Cortigent, Inc. (“Cortigent”).... Read More